Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Volume picked up a bit
View:
Post by fredgoodwinson on Sep 30, 2021 4:09pm

Volume picked up a bit

with the price fall at the close.

Trusting that this afternoon`s 'sell' advice from the poster over on CEO was b/s rather than anything more substantive but it would be nice if we heard something - in fact anything - from our new CEO.
Comment by gojotv! on Sep 30, 2021 5:09pm
No doubt every scammer and basher worth his salt will be on this one this month. We are approaching announcements about efficacy in our latest patients, and with minimal side effects and no reported toxicity, it looks like the data will be very positive. Fast Track Status has been achieved, and Breakthrough Status is within reach. And that changes everything. Those with strong hands will prevail ...more  
Comment by 99942Apophis on Sep 30, 2021 5:11pm
fredgoodwinson wrote with the price fall at the close. Trusting that this afternoon`s 'sell' advice from the poster over on CEO was b/s rather than anything more substantive but it would be nice if we heard something - in fact anything - from our new CEO. Hi fredgoodwinson my opinion with today's and most days trade activity its mostly shorters & hedge funds along with their ...more  
Comment by fredgoodwinson on Sep 30, 2021 5:57pm
Hi Apophis - yes no stranger to manipulation here and this is likely some of the same but uncertainty can only thrive in a vacuum and as has been pointed out before some CEO`s of small caps commendably take on shorters and the like directly with their shareholders - something that in the moral vacuum that exists among the Politicians and Regulators can give significant comfort to retail ...more  
Comment by BuenaSuertaAtod on Oct 01, 2021 8:37am
Was that www.ceo.ca that you're referring to? Did they have any logic to back up that advice? -TIA!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250